Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Invested Capital (2020 - 2024)

Historic Return on Invested Capital for C4 Therapeutics (CCCC) over the last 5 years, with Q4 2024 value amounting to 0.52%.

  • C4 Therapeutics' Return on Invested Capital rose 900.0% to 0.52% in Q4 2024 from the same period last year, while for Dec 2024 it was 0.52%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.52% for FY2024, which is 0.0% changed from last year.
  • C4 Therapeutics' Return on Invested Capital amounted to 0.52% in Q4 2024, which was up 900.0% from 0.49% recorded in Q3 2024.
  • In the past 5 years, C4 Therapeutics' Return on Invested Capital registered a high of 0.37% during Q3 2020, and its lowest value of 0.89% during Q4 2020.
  • For the 5-year period, C4 Therapeutics' Return on Invested Capital averaged around 0.35%, with its median value being 0.48% (2024).
  • As far as peak fluctuations go, C4 Therapeutics' Return on Invested Capital tumbled by -3000bps in 2023, and later surged by 1200bps in 2024.
  • C4 Therapeutics' Return on Invested Capital (Quarter) stood at 0.89% in 2020, then skyrocketed by 72bps to 0.25% in 2021, then dropped by -24bps to 0.31% in 2022, then crashed by -96bps to 0.61% in 2023, then grew by 14bps to 0.52% in 2024.
  • Its Return on Invested Capital stands at 0.52% for Q4 2024, versus 0.49% for Q3 2024 and 0.48% for Q2 2024.